Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir

Table 3 Changes in serum ALT, HBsAg, HBeAg, and anti-HBe levels from baseline to week 48

Variable	ETV group (n = 30)	TAF group (n = 30)	P value
ALT (U/L)	-16.7 ± 21.4	-18.3 ± 19.6	0.72
HBsAg (log 10 IU/mL)	-0.1 ± 0.3	-0.2 ± 0.4	0.31
HBeAg (S/CO)	-1.2 ± 2.4	-1.4 ± 2.6	0.69
Anti-HBe (S/CO)	0.2 ± 0.5	0.8 ± 1.1	0.03

Data are presented as mean ± SD. ETV: Entecavir; TAF: Tenofovir alafenamide; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen.